Quest Diagnostics, Inc.

Quest Diagnostics, Inc.

DGX

Get informed when a big investor buys or sells

+ Follow
Market Cap$21.57B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Quest Diagnostics, Inc.Quest Diagnostics, Inc.20.91.67%14%1.90.9

Earnings Call Q1 2026

April 21, 2026 - AI Summary

Strong Q1 momentum; raising full-year guidance - Revenues: $2.9B, +9.2% YoY (mostly organic +9%). - Adjusted EPS: $2.50, +~13% YoY (reported EPS $2.24). - Company credited automation + AI productivity and broad-based clinical innovation demand. - Guidance raised (full-year 2026): - Revenue: $11.78B–$11.9B (+6.8% to +7.8% growth). - Reported EPS: $9.58–$9.78; Adjusted EPS: $10.63–$10.83. - Cash from ops: ~$1.75B; Capex: ~$550M.
Volume & mix: utilization strong, but mix headwind from major collaborations - Total volume (requisitions): +10.9% YoY; organic volume +10.8%. - Contribution from Fresenius Medical Care + Corewell Health: ~7% of organic volume growth. - Excluding Fresenius/Corewell, organic volume growth was ~3.8%. - Revenue per requisition (RPQ): -1.3% YoY overall due to mix (more routine tests from those partnerships). - Excluding Fresenius/Corewell mix impact, RPQ was ~+2.5% driven by more tests per requisition (more advanced/early-detection/screening panels). - Management highlighted ongoing positive “test per req” trend as a key driver going forward.
Channel performance: broad-based growth + notable clinical innovation wins - Physician channel: high single-digit growth; geographic expansion via health plan access and enterprise accounts. - Hospital channel: double-digit growth; majority attributed to collaborative Co-Lab with Corewell Health (implementation “proceeding smoothly”). - End-stage renal disease (ESRD): growth in a new clinical area—dialysis-related testing for Fresenius clinics plus added independent clinics/providers. - Consumer channel: strong growth across QuestHealth.com and partnerships (wearables/apps). Questhealth.com featured robust double-digit repeat rates and demand for new tests (e.g., Elite health profile, autoimmune/hormone). - Clinical areas with double-digit growth mentioned: brain health (AD-Detect), cardiometabolic/endocrine (incl. Lp(a), ApoB), autoimmune, oncology (Haystack MRD collaboration w/ City of Hope), women’s/reproductive health.

Exclusive for Stockcircle Pro members

Sign upSign Up
$220.44

Target Price by Analysts

13.8% upsideQuest Diagnostics Target Price DetailsTarget Price
$231.85

Current Fair Value

19.7% upside

Undervalued by 19.7% based on the discounted cash flow analysis.

Share Statistics

Market cap$21.57 Billion
Enterprise Value$28.16 Billion
Dividend Yield$3.26 (1.67%)
Earnings per Share$8.87
Beta0.6
Outstanding Shares110,000,000

Return

Return on Equity13.89%ROE
Return on Assets6.14%
Return on Invested Capital11.38%

Valuation & Multiples

P/E Ratio20.94P/E Ratio
PEG143.94PEG
Price to Sales1.9Price to Sales
Price to Book Ratio2.81Price to Book Ratio
Enterprise Value to Revenue2.5
Enterprise Value to EBIT17.08
Enterprise Value to Net Income27
Total Debt to Enterprise0.25
Debt to Equity0.95Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
April 28, 2026
EPS Estimate
$2.37
Average shareholder expectation
Revenue Estimate
$2.83 B
Average shareholder expectation

Next Earnings Call

Expected Date
July 28, 2026
EPS Estimate
$2.81
Average shareholder expectation
Revenue Estimate
$2.98 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.4052▼ 31.93%
Total Calls405,200▲ 5.99%
Total Puts164,200▼ 40.72%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %91.95%▼ 2.79%
Total Invested$19.99B▲ 8.73%
Investors Holding1,071▲ 4.00%

ESG Score

No data

About Quest Diagnostics, Inc.

47,000 employees
CEO: Stephen Rusckowski

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy beh...

Relevant Senate Committees

Finance

As the primary committee for taxation, trade, and entitlement spending, it directly impacts Quest Diagnostics through corporate tax policy and, critically, by influencing Medicare/Medicaid reimbursement rates, which are major revenue drivers for clinical laboratories.

Appropriations

This committee directly allocates federal discretionary spending. Its subcommittees determine funding for various healthcare programs (Medicare, Medicaid, VA) which provide significant revenue to Quest Diagnostics for its services, making it a critical source of financial influence.

Health, Education, Labor, and Pensions

This committee directly regulates key aspects of Quest Diagnostics' business, including FDA oversight of diagnostic tests (IVDs), NIH funding for health research, and labor laws affecting its 47,000 employees. Changes in these areas directly impact DGX's operations and costs.

Veterans' Affairs

Quest Diagnostics likely serves veterans through the Department of Veterans Affairs or related programs. This committee's funding decisions directly impact government healthcare contractors and the delivery of healthcare services to veterans, a significant client base for Quest Diagnostics.